Clinical Trial Update: Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing once-daily mesalazine 4 g to 4 g given in two divided doses for active ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Mesalazine (mesalazine)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED